PureTech Founded Entity Seaport Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial Evaluating GlyphAgo™ in Patients with Generalized Anxiety Disorder and Sleep Disturbance
Key Highlights
- ➤Seaport (SPTX) doses first patient in Phase 2a GlyphAgo trial for GAD and sleep disturbance
- ➤Phase 2a topline data expected in early 2028
- ➤Seaport plans global Phase 2/3 GAD trial initiation in first half of 2027
- ➤Phase 1 showed GlyphAgo bioavailability 6.8-fold higher than unmodified agomelatine
- ➤Phase 1 reported no serious, severe, or liver-related adverse events after seven days
Expert Statements
Daphne Zohar, Co-Founder and Chief Executive Officer at Seaport Therapeutics
“Anxiety disorders affect more than 300 million people globally(3), and place a substantial burden on patients, families, and healthcare systems. Patients with generalized anxiety disorder experience persistent anxiety symptoms that can make it difficult to carry out normal activities, and sleep disturbances are among the most frequently reported debilitating symptoms. Despite the widespread impact of GAD, there have been no new approved therapies in almost two decades, and many patients continue to experience inadequate symptom relief or tolerability issues that limit treatment. The initiation of this trial is an important step in bringing this potential new medicine to patients and their families.”
Daniel Bonner, Ph.D., Co-Founder and Senior Vice President, Platform, at Seaport Therapeutics
“Agomelatine has been shown to improve sleep quality and sleep architecture without the daytime sleepiness seen with other therapies, making it a compelling candidate for patients with GAD and sleep disturbance. We designed GlyphAgo with our Glyph™ platform to bypass first-pass liver metabolism and address the bioavailability and hepatic limitations of unmodified agomelatine. We believe that GlyphAgo represents a potentially important treatment advance for people with GAD.”
PureTech Founded Entity Seaport Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial Evaluating GlyphAgo™ in Patients with Generalized Anxiety Disorder and Sleep Disturbance
PureTech Health plc (LSE: PRTC) ("PureTech" or the "Company"), a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into value, notes that its Founded Entity, Seaport Therapeutics, today announced that the first patient has been dosed in a Phase 2a clinical trial in Australia evaluating GlyphAgo™ (SPT-320 or Glyph Agomelatine) in adults with generalized anxiety disorder (“GAD”) and sleep disturbance. The six-week trial is designed to establish proof-of-pharmacology by evaluating the effects of GlyphAgo on sleep. Seaport expects to report topline data from the trial in early 2028.
Get started
Create a free account to read the full story.